US FDA approves pomalidomide for AIDS-related and HIV-negative Kaposi Sarcoma

The approval was based on the findings of a phase 1/2 open-label, single-arm study evaluating the safety, pharmacokinetics and efficacy of pomalidomide in patients with HIV-positive and HIV-negative symptomatic Kaposi sarcoma.

Source:

Biospace Inc.